Skip to main content
Clinical Trials/EUCTR2016-002595-27-NL
EUCTR2016-002595-27-NL
Active, not recruiting
Phase 1

Cytoreductive surgery and Intraperitoneal chemotherapy and for Stomach CAncer: a feasibility study - CISCA

niversity Medical Center Utrecht0 sites20 target enrollmentMarch 23, 2017

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Peritoneal carcinomatosis of gastric origin
Sponsor
niversity Medical Center Utrecht
Enrollment
20
Status
Active, not recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 23, 2017
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Eligibility Criteria

Inclusion Criteria

  • \-Histologically proven adenocarcinoma of the stomach.
  • \-Surgical resectable carcinoma (T1\-4a, N1\-3\) (table 1\)
  • \-Clinical or pathological proven peritoneal metastases
  • \-Peritoneal Cancer Index (PCI) \=12
  • \-European Clinical Oncology Group (ECOG) performance status 0,1 or 2
  • \-Age \= 18
  • \-Written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes

Exclusion Criteria

  • \- Distant metastases other than peritoneal metastases
  • \- Siewert type I gastro\-esophageal junction tumor.
  • \- Peritoneal carcinomatosis as a presentation of recurrent disease
  • \- Pregnancy
  • \- Contraindication to cisplatin (e.g. hypersensitivity, HIV infection and inadequate bone marrow, hepatic or renal function)

Outcomes

Primary Outcomes

Not specified

Similar Trials